TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ARTV stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tyler Van Buren has given his Buy rating due to a combination of factors that highlight Artiva Biotherapeutics, Inc.’s promising developments in the field of cell therapy for autoimmune diseases. The company’s AlloNK therapy has demonstrated impressive safety and efficacy data, particularly in terms of B-cell depletion, which sets it apart from other therapies in the autoimmune space.
Artiva’s initial clinical data from trials involving 32 patients showed no severe adverse effects typically associated with cell therapies, such as ICANS or CRS, reinforcing the differentiated mechanism of AlloNK. Additionally, the therapy’s ability to achieve consistent and complete B-cell depletion, coupled with the potential for immune reset, supports its potential adoption in the community setting. The anticipated efficacy data from refractory RA patients in 2026 further strengthens the outlook for Artiva’s innovative approach.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $15.00 price target.